U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07648459) titled 'CM336-SOC for Dynamically High-Risk Multiple Myeloma Study' on June 08.
Brief Summary: This is a single-arm, open-label study to evaluate the efficacy and safety of CM336 combined with SOC therapy in patients with dynamically high-risk multiple myeloma.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: anti-BCMA/CD3 bispecific antibody
Anti-BCMA/CD3 bispecific antibody (CM336) will be administered via a subcutaneous injection (SC).
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Published by HT Digital Content Servic...